We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm
News

genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm

genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm
News

genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "genOway Signs a $2 Million Contract with a US-based Biopharmaceutical Firm"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

genOway reports the signing of a contract for up to $2 million in intended services with a leading biopharmaceutical company based in the United States of America.

Under the terms of this 2-year agreement, genOway will provide its client with customized genetically modified mouse lines tailored to the researchers’ needs. Moreover, this agreement can be increased to include additional models.

genOway has been chosen thanks to the company’s expertise and capacity to create highly sophisticated animal models by means of an industrialized production process.

"This contract is the second multi-million dollar deal of the year for genOway. It further confirms that the company is able to propose acceptable offers to large biopharmaceutical companies. genOway is proud to have been chosen by this company and we are very excited about the start of this collaboration" said Alexandre Fraichard, CEO of genOway.

Advertisement